

RESEARCH ARTICLE

Strength of T cell signaling regulates HIV-1 replication and establishment of latency

Matthew Gagne¹, Daniel Michaels^{1,2}, Gillian M. Schiralli Lester³,
Suryaram Gummuluru¹, Wilson W. Wong^{4,5}, Andrew J. Henderson^{1,2*}

1 Department of Microbiology, Boston University School of Medicine, Boston, MA, United States of America, **2** Department of Medicine, Section of Infectious Diseases, Boston University Medical Center, Boston, MA, United States of America, **3** Department of Pediatrics, Neonatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, United States of America, **4** Department of Biomedical Engineering, Boston University, Boston, MA, United States of America, **5** Biological Design Center, Boston University, Boston, MA, United States of America

* andrew.henderson@bmc.org



OPEN ACCESS

Citation: Gagne M, Michaels D, Schiralli Lester GM, Gummuluru S, Wong WW, Henderson AJ (2019) Strength of T cell signaling regulates HIV-1 replication and establishment of latency. *PLoS Pathog* 15(5): e1007802. <https://doi.org/10.1371/journal.ppat.1007802>

Editor: Ronald Swanstrom, University of North Carolina at Chapel Hill, UNITED STATES

Received: March 6, 2019

Accepted: April 30, 2019

Published: May 22, 2019

Copyright: © 2019 Gagne et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: This work was supported by NIH grants AI 138960 and AI 097117 to AJH, and NIH F31 AI 129195 to MG. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Abstract

A major barrier to curing HIV-1 is the long-lived latent reservoir that supports re-emergence of HIV-1 upon treatment interruption. Targeting this reservoir will require mechanistic insights into the establishment and maintenance of HIV-1 latency. Whether T cell signaling at the time of HIV-1 infection influences productive replication or latency is not fully understood. We used a panel of chimeric antigen receptors (CARs) with different ligand binding affinities to induce a range of signaling strengths to model differential T cell receptor signaling at the time of HIV-1 infection. Stimulation of T cell lines or primary CD4+ T cells expressing chimeric antigen receptors supported HIV-1 infection regardless of affinity for ligand; however, only signaling by the highest affinity receptor facilitated HIV-1 expression. Activation of chimeric antigen receptors that had intermediate and low binding affinities did not support provirus transcription, suggesting that a minimal signal is required for optimal HIV-1 expression. In addition, strong signaling at the time of infection produced a latent population that was readily inducible, whereas latent cells generated in response to weaker signals were not easily reversed. Chromatin immunoprecipitation showed HIV-1 transcription was limited by transcriptional elongation and that robust signaling decreased the presence of negative elongation factor, a pausing factor, by more than 80%. These studies demonstrate that T cell signaling influences HIV-1 infection and the establishment of different subsets of latently infected cells, which may have implications for targeting the HIV-1 reservoir.

Author summary

Activation of CD4+ T cells facilitates HIV-1 infection; however, whether there are minimal signals required for the establishment of infection, replication, and latency has not been explored. To determine how T cell signaling influences HIV-1 infection and the generation of latently infected cells, we used chimeric antigen receptors to create a tunable model. Stronger signals result in robust HIV-1 expression and an inducible latent

population. Minimal signals predispose cells towards latent infections that are refractory to reversal. We discovered that repression of HIV-1 transcription immediately after infection is due to RNA polymerase II pausing and inefficient transcription elongation. These studies demonstrate that signaling events influence the course of HIV-1 infection and have implications for cure strategies. They also provide a mechanistic explanation for why a significant portion of the HIV-1 latent reservoir is not responsive to latency reversing agents which function by modifying chromatin.

Introduction

HIV-1 persists in a transcriptionally silent latent state in long-lived memory T cells. Although antiretroviral therapies (ART) suppress HIV-1 replication, interruption of treatment results in rapid viral rebound. Therefore, HIV-1 patients must remain on ART indefinitely, despite long-term side effects, development of treatment resistance, and viral-induced inflammation [1–3]. For this reason, one strategy currently being explored for cure efforts is “shock and kill,” in which latent HIV-1 is reactivated in conjunction with ART using latency-reversing agents (LRAs). Following reactivation, infected cells are predicted to be eliminated by HIV-specific immunity or virally induced apoptosis. However, clinical trials using LRAs have only minimally perturbed the size of the viral reservoir [4–6].

A cure for latent HIV-1 will require a better understanding of the biochemical factors involved in regulating proviral transcription. Latency in chronically infected primary cells and cell lines is regulated by multiple transcriptional mechanisms including NF- κ B activation, chromatin accessibility, provirus transcription initiation, Tat availability, P-TEFb sequestration, and transcriptional elongation [7–11]. However, what is not understood is how latency is initially established within a cell and if events at the time of HIV-1 infection influence the transcriptional status of the provirus. These questions are relevant since the latent reservoir is established within the first two weeks of infection [12,13]. New cure strategies will need to limit the size of the reservoir at early time points.

One mechanism that could predispose HIV-1 towards active replication or transcriptional repression and latency is signaling through the T cell receptor (TCR). Engagement of the TCR and costimulatory CD28 molecule result in a multitude of cellular outcomes that influence HIV-1 replication including cytoskeleton reorganization, the activation of transcription factors, enhanced RNA polymerase II (RNAP II) processivity, and chromatin remodeling [14–16]. We hypothesized that the magnitude of T cell signaling during HIV-1 infection will dictate the course of the infection. In order to manipulate signal strength received by a T cell at the time of HIV-1 infection, we utilized chimeric antigen receptors (CARs) that recapitulate T cell receptor and CD28 signaling. By modulating the affinity with which these CARs bind to their ligand, we can differentially deliver signals to target cells.

Using these CARs, we demonstrate that stronger T cell signaling at the time of HIV-1 infection increases subsequent HIV-1 transcription and replication. Robust signals also facilitated the formation of latently infected cells that were readily inducible upon secondary stimulation. Minimal signaling through CARs, although sufficient for HIV-1 integration, failed to support viral replication and generated a deep-seated latent infection. Transcriptional elongation of HIV-1 provirus was limited by RNAPII pausing in the absence of CAR signaling; however, strong CAR signaling correlated with decreased negative elongation factor (NELF) binding and enhanced RNAPII processivity. Our results suggest a model in which signaling strength

influences HIV-1 transcription and establishment of latency at the time of initial infection of CD4+ T cells.

Results

CARs induce T cell signaling

To examine how signaling cascades downstream from the T cell receptor regulate HIV-1 transcription we utilized CARs (Fig 1A). Intracellular signaling domains for the CARs include CD3 ζ with its immunoreceptor tyrosine-based activation motifs (ITAMs) and the CD28 costimulatory domain with its four critical tyrosine residues [17]. Furthermore, a mCherry tag provides a marker for positive selection of CAR+ cells. The extracellular ligand-binding domains of the CARs consist of a single chain variable fragment (scFv) that recognizes receptor tyrosine-protein kinase erbB-2 (Her2) [18,19]. By using different scFvs, a library of CARs with binding affinities for Her2 ligand spanning three logs was generated (Fig 1B). CARs were




Fig 1. Chimeric antigen receptors used for tunable T cell signaling. (A) The design of CARs including CD3 ζ and CD28 signaling domains. (B) CAR single chain variable fragments with their corresponding dissociation constants for the Her2 ligand. We refer to these CARs by their relative ligand affinity. (C) Enrichment of primary CD4+ T cells based on mCherry expression following CAR transduction.

<https://doi.org/10.1371/journal.ppat.1007802.g001>

transduced into Jurkat T cells and primary CD4⁺ T cells. By enriching for mCherry, we obtained CAR⁺ populations that were >90% pure (Fig 1C).

We confirmed that signaling through CARs mimicked aspects of TCR signaling and supported differential changes in both downstream gene expression and T cell phenotypes. CD69, a transmembrane lectin and a marker for CD4⁺ T cell activation, was monitored by flow cytometry before and after receptor activation with Her2 ligand (Fig 2A). Primary CD4⁺ T cells transduced with either the low affinity or the high affinity receptors were stimulated with plate-bound Her2 ligand for 24 h. In the absence of ligand, less than 7% of the cells were positive for CD69, verifying that there is no ectopic CAR signaling. Activating cells with Her2 induced CD69 expression in the low affinity and high affinity receptors relative to their affinity for ligand. In addition, we analyzed the ability of the receptors to generate T cell subsets one week post stimulation by determining the expression of CCR7, a lymph node homing receptor, and CD45RA, a marker that is downregulated on memory subsets following activation through endogenous TCR. Similar expansion of CCR7⁺ CD45RA⁻ T cell populations was observed in cells stimulated through the TCR and both the high and low affinity CARs (Fig 2B).

Finally, microarray analysis was performed to determine if CAR and TCR signaling resulted in similar global gene expression changes. A heatmap of genes whose expression was significantly altered compared to baseline upon activation through either the high and low affinity CARs or treatment with anti-CD3 and anti-CD28 is shown in S1 Fig. A spectrum of changes in gene expression downstream from the T cell receptor was observed that included subsets of genes that were induced or repressed to similar extents by the TCR and CARs as well as more graded differential responses in which the high and low affinity CARs induced intermediate changes as compared to the T cell receptor. We did observe donor-to-donor variation, which was expected. This may reflect intrinsic donor variation as well as sexual dimorphism because of the inclusion of 1 male and 2 female donors. Together with the CD69 analysis and memory cell markers, these data demonstrate that signaling through the chimeric antigen receptors facilitate a range of cellular effects associated with T cell activation and that the CARs can be used as tools to modulate T cell signals.

T cell signaling at the time of HIV-1 infection regulates provirus expression

To determine whether T cell signaling influences viral infection, Jurkat T cells expressing low affinity or high affinity CARs were plated on Her2-coated wells and simultaneously infected with VSV-G pseudotyped NL4-3.Luc, a single-cycle HIV-1 clone which contains a luciferase reporter in place of Nef. VSV-G allowed us to bypass potentially confounding effects from receptor/chemokine receptor signaling due to gp120 binding and focus specifically on CAR-associated signaling cascades. To assess whether signaling influenced the establishment of infection, we measured levels of HIV-1 proviral DNA using a previously described nested *Alu*-PCR approach [20]. We modified the assay by designing primers to luciferase to estimate the relative frequency of HIV-1 integration without confounding signals from the lentiviral vectors used to express the CARs (see [Materials and Methods](#)). CAR-associated signaling did not affect the infection of Jurkat cells since we detected comparable levels of provirus regardless of the presence or absence of CAR ligand (Fig 3A). When HIV-1 expression was measured by luciferase activity, Jurkat cells infected in the context of strong T cell signaling expressed greater than 10-fold more HIV-1 compared to untreated controls (Fig 3B). In contrast, engagement of the low affinity receptor led to a modest 3-fold expression compared to unstimulated cells despite a similar proviral load as the high affinity CAR-expressing cells. These data




Fig 2. Signaling through chimeric antigen receptors results in T cell maturation. CD4+ T cells isolated from healthy human donors were transduced with low affinity or high affinity CARs and then allowed to return to a resting

state. (A) Cells in Panel A were stimulated through the receptor or left unstimulated. CD69 expression one day after Her2 stimulation was compared to a negative control of untransduced cells. (B) CAR-expressing primary cells were stimulated through the receptor for two days and compared to untransduced cells treated with or without antibodies to CD3 and CD28 at a ratio of 1:1. Analysis was performed 7 days post stimulation, and cells were cultured in IL-7 and IL-2 during the intervening period. The use of CCR7 and CD45RA can be used to classify cells into three distinct populations: CCR7⁺ CD45RA⁺ naïve-like cells, CCR7⁺ CD45RA⁻ central memory cells, and CCR7⁻ CD45RA⁻ effector memory cells. Data in A and B are presented as dot plots based on flow cytometry analysis and is from a representative experiment that has been performed at least three times with different donors.

<https://doi.org/10.1371/journal.ppat.1007802.g002>

indicate that strong T cell signaling at the time of infection facilitates HIV-1 expression without enhancing provirus integration.

We confirmed that these differences were due to downstream signaling emanating from the CARs by using the Src kinase inhibitor PP2. In the presence of PP2, the increase in HIV-1 expression upon cellular stimulation was attenuated, consistent with T cell signaling as a regulator of HIV-1 expression (S2 Fig). The pharmacologically inactive version of this inhibitor, PP3, had no effect on the ability of CARs to influence HIV-1 expression.

We validated these results using primary CD4⁺ T cells that were transduced with either the low affinity or high affinity CAR. Following transduction, cells were allowed to return to a resting state as monitored by low CD69 expression before infection with HIV-1 in the absence or presence of the ligand Her2. Consistent with the data from Jurkat cells, similar levels of proviral DNA were detected in primary T cells regardless of CAR signaling (Fig 3C). Depending on the donor, cells that received robust stimulation at the time of infection expressed 2.5- to 11-fold more HIV-1 compared to untreated controls. Stimulating through the low-affinity CARs led to more modest luciferase expression when compared to untreated cells (Fig 3D).

To gain insight into whether there is a threshold or minimal T cell signal required for HIV-1 infection and replication, we transduced Jurkat T cells with CARs that spanned a range of binding affinities (Fig 1B). These cells were infected with NL4-3.Luc as described above in the absence or presence of Her2. Although the high affinity condition supported HIV-1 infection and transcription, the intermediate and low affinity receptors did not support HIV-1 expression (Fig 4A). This was despite similar levels of infection as determined by measuring proviral DNA (Fig 4B) and a greater than 10-fold increase in binding affinity for the Her2 ligand above that of the low affinity CARs. These data suggest that T cell signaling controls HIV-1 expression by a digital on/off mechanism since viral expression does not linearly correlate with signal strength.

Robust signals during HIV-1 infection establish an inducible latent reservoir

We hypothesized that differential T cell signaling during infection alters the size of the inducible latent reservoir. To examine this, we infected CAR-expressing primary CD4⁺ T cells with VSV-G pseudotyped BRU-dENV-GFP in the presence of Her2 ligand. One week post infection, cells were sorted for both mCherry expression as a marker for the CAR and lack of GFP expression in order to enrich for latently infected cells. CAR^{pos}/GFP^{neg} cells were reactivated with PMA plus ionomycin or left unstimulated to control for spontaneous HIV-1 reactivation (Fig 5A). PMA plus ionomycin significantly reactivated HIV-1 expression within cells that had been initially infected in the context of high-affinity CAR, resulting in a 3- to 9-fold increase in the percentage of GFP positive cells (Fig 5B) and a 1000-fold induction of HIV-1 mRNA measured by qRT-PCR (Fig 5C, S3 Fig). However, the observed reactivation of HIV-1 was modest in cells infected at the time of stimulation through the low affinity CAR. Less than a 2-fold change was observed in the percentage of GFP⁺ cells, and only a 200-fold induction of HIV-1




Fig 3. T cell signaling at the time of HIV-1 infection regulates provirus expression. (A and B) Jurkat T cells were transduced with the high or low affinity CAR. Cells were stimulated through CARs at the time of HIV-1 infection with VSV-G pseudotyped NL4-3.Luc. (A) Relative levels of integrated provirus 24 h post infection of high or low affinity Jurkat T cells using nested *Alu*-PCR. Uninfected CAR-expressing Jurkat T cells were a negative control. (B) Luciferase activity measured 24 h post-infection presented as fold difference in relative light units (RLUs) over unstimulated cells for each CAR+ cell line. Panels A and B were performed in triplicate and are representative of four independent experiments. Data are presented as mean \pm standard deviation. (C and D) Primary CD4⁺ T cells isolated from healthy human donors were transduced with CARs and given one week to return to a resting state. Cells were stimulated through CARs at the time of HIV-1 infection with single-round VSV-G pseudotyped NL4-3.Luc. (C) Relative levels of integrated provirus 24 h after infection of high or low affinity CAR-expressing primary T cells (from the same donor) using nested *Alu*-PCR. Uninfected CAR-expressing primary T cells were a negative control. Results are from a single experiment performed in triplicate and are representative of two independent experiments. Data are presented as mean \pm standard deviation. (D) Luciferase activity measured 4 days post-infection presented as fold difference in RLUs over unstimulated cells for each CAR+ cell line. Experiments from two separate donors are shown and are representative of three independent experiments. Statistical analysis performed using unpaired Student's *t* test. **p*<0.01, ***p*<0.001, ****p*<0.0001.

<https://doi.org/10.1371/journal.ppat.1007802.g003>

mRNA was detected in reactivated latently infected cells expressing low affinity CARs. Thus, there was a ~5-fold increase in HIV-1 mRNA induction for cells expressing high affinity CAR upon reactivation compared to reactivation in cells expressing low affinity CAR (Fig 5C, S3 Fig).

A panel of latency reversing agents were tested for their abilities to reactivate the latently infected cells generated by the different CARs. Cells were reactivated with antibodies to CD3 and CD28, the HDAC inhibitor SBHA, and the PKC agonist Bryostatin (Fig 5B). Secondary stimulation through the endogenous T cell receptor with anti-CD3+CD28 reactivated latent HIV-1 in cells that had been infected and stimulated through the high-affinity receptor, resulting in a 3- to 7-fold increase in the percentage of GFP positive cells. However, anti-CD3+CD28 treatment resulted in either no reactivation or a modest 1.8-fold reactivation in cells stimulated through the low affinity CAR at the time of HIV-1 infection. SBHA did not strongly induce HIV-1 expression but there was a trend of greater virus reactivation in cells that had received stronger TCR signaling at the time of HIV-1 infection. Treatment with Bryostatin did not lead to robust activation for either low affinity or high affinity CAR-expressing cells. In general, there appeared to be different reservoir sensitivities to latency reversal agents between cells that had received strong or weak signaling during infection, especially when comparing cells derived from the same donor. Our data suggest that despite comparable amounts of integrated HIV-1 proviruses, robust signaling at the time of infection was not only necessary for active proviral transcription but also supported the generation of a population of latently infected cells that could be readily induced to express HIV-1. The population of latent cells generated in response to weaker CAR signaling was more resistant to latency reversal suggesting that HIV-1 in these cells was strongly repressed.

RNAP II processivity limits HIV-1 transcription in the absence of robust signaling

We were interested in mechanisms that governed HIV-1 repression following integration in the absence of sufficient T cell signaling; therefore, we examined the binding of transcriptional regulators on the HIV-1 LTR by chromatin immunoprecipitation (ChIP). Jurkat T cells expressing low or high affinity CARs were infected with NL4-3.Luc in the absence or presence of Her2 ligand. One day post-infection, cells were fixed and chromatin was prepared for ChIP.

Since HIV-1 proviral latency correlates with a positioned nucleosome that is downstream of the transcriptional start site, we explored whether the LTR was associated with post-translationally modified histones as an indicator of chromatin organization. ChIPs for acetylated




Fig 4. Robust T cell signaling is required for HIV-1 transcription. (A) Jurkat T cells were transduced and positively selected for indicated CARs and then infected with VSV-G pseudotyped NL4-3.Luc. 24 h post infection, cells were lysed for luciferase analysis. Data are presented as fold difference in RLU over unstimulated cells for each CAR + population. (B) Relative levels of integrated provirus after infection of CAR-expressing Jurkat cells using nested *Alu*-PCR. Panels A and B were performed in triplicate and are representative of four independent experiments. Data are presented as mean \pm standard deviation. Statistical analysis performed using unpaired Student's *t* test. * $p < 0.01$, ** $p < 0.001$, *** $p < 0.0001$.

<https://doi.org/10.1371/journal.ppat.1007802.g004>




Fig 5. Robust signals during HIV-1 infection establish an inducible latent reservoir. (A) Outline of experimental plan to enrich for latently infected cells following infection. Primary CD4+ T cells are infected with VSV-G pseudotyped BRU-ΔEnv-GFP and GFP-negative cells are sorted to enrich for latently infected cells. (B) Percent GFP+ HIV-expressing cells after stimulation of latent cells with various latency-reversing agents: PMA plus ionomycin, antibodies to

endogenous CD3 and CD28, SBHA, and Bryostatins. Data are from seven separate donors as indicated by the color code of samples, and each LRA stimulation was performed on cells from 2–3 donors. A minimum of 250 events was required for inclusion as a data point. We had a range of 250 to 6000 events per data point depending on both donor variability and cell viability due to stimulation condition. The mean value for all data points was 1364 events and the median was 678 events. (C) Latently-infected cells were restimulated with PMA and ionomycin. HIV-1 expression was monitored by measuring Tat RNA by qRT-PCR. Values are shown as fold difference in HIV-1 transcripts over corresponding non-reactivated controls. All data in panel C are derived from 4–6 replicates and are representative of four independent experiments (see also S3 Fig). Data are presented as mean \pm standard deviation. Statistical analysis performed using unpaired Student's *t* test. * $p < 0.01$, ** $p < 0.001$, *** $p < 0.0001$.

<https://doi.org/10.1371/journal.ppat.1007802.g005>

histone H3 showed no significant difference in binding of the HIV-1 LTR between cells infected in the absence or presence of T cell signaling (Fig 6A). Therefore, chromatin accessibility does not appear to be limiting HIV-1 proviral transcription following infection.

We then examined RNAP II processivity by measuring RNAP II occupancy at multiple points, including the transcriptional start site and downstream in the HIV-1 *tat* gene. RNAP II was detected at the HIV-1 transcriptional start site whether cells were activated through a CAR or were unstimulated (Fig 6B). However, signaling through the high affinity receptor resulted in an increase in downstream RNAP II by greater than 4-fold, whereas only modest levels of RNAP II were found downstream in the absence of signals or following weak signaling (Fig 6C).

Since these data indicated a role for transcriptional pausing, we examined if CAR signaling altered the presence of the pausing factor negative elongation factor (NELF) at the HIV-1 transcriptional start site. Using ChIPs, we determined that signaling through the high affinity receptor diminished binding of NELF at the HIV-1 LTR by greater than 85% (Fig 6D). These data support a model in which a lack of robust T cell signaling limits HIV-1 transcription by establishing a paused polymerase complex.

Discussion

Previous studies suggest that cell signaling may be a key regulator of HIV-1 expression and latency. The latent reservoir is enriched for antigen specific T cells, including those that respond to CMV, HSV, tuberculosis, and HIV [21–25]. Furthermore, the use of superantigens during viral entry increases HIV-1 replication [26]. Partial activation, cellular polarization, cell-to-cell contact, and/or infection of resting quiescent cells through perturbation have also been suggested to bias infections towards latency [11,27–31]. Therefore, the extent of cell activation is a key determinant in regulating the course of HIV-1 infection including the formation of the reservoir.

We have shown that differential signaling through CARs, which mimic TCR signaling, influences HIV-1 transcription and latency. In the lymph node, a primary site for both HIV-1 replication and the persistent latent reservoir [32–34], T cells will sample lymph node resident cells in search for antigen. Some of these interactions, facilitated by the presentation of the T cell cognate antigen, will result in robust T cell activation, clonal expansion, and changes in gene expression. However, most MHC complexes will lack cognate antigen and initiate weak signaling [35,36]. Using multiple CARs whose affinities for the Her2 ligand span several logs, we can deliver a range of signaling inputs to model the spectrum of T cell receptor signaling events. Our data indicates that stronger T cell activation at the time of infection, which would be more similar to antigen specific responses, correlates with robust HIV-1 expression as well as the establishment of inducible latently infected cells. We validated these findings in both Jurkat cell lines and primary CD4+ T cells derived from multiple donors although the magnitude of responses from primary cells was more variable as would be predicted. Additional factors may compensate for suboptimal T cell receptor signaling including cytokine-induced stimulation and interactions with antigen presenting cells that would engage both




Fig 6. RNAP II processivity limits HIV-1 transcription in the absence of robust signaling. CAR-expressing Jurkat T cells were infected with single-round VSV-G NL4-3.Luc and simultaneously plated with or without Her2 ligand. 24 h later, cells were fixed for chromatin immunoprecipitation. (A) ChIP for presence of acetylated H3 near the transcriptional start site (nuc1). (B) ChIP for RNAP II at the HIV-1 transcriptional start site. (C) ChIP for RNAP II associated with the HIV-1 *tat* gene to measure RNAP II processivity. Data from A-C are normalized to corresponding IgG controls for each stimulation condition. (D) ChIP for NELF-d at the HIV-1 transcriptional start site. Data is normalized to IgG controls and then to corresponding unstimulated condition for each CAR+ cell line. A-D were performed in triplicate and are representative of at least three independent experiments in Jurkat T cells. Data are presented as mean \pm standard deviation. Primers used for HIV-1 transcriptional start site are +30 and +239. Primers used for *tat* gene are +5379 and +5482. Statistical analysis performed using unpaired Student's *t* test. * $p < 0.01$, ** $p < 0.001$, *** $p < 0.0001$.

<https://doi.org/10.1371/journal.ppat.1007802.g006>

costimulatory molecules and inhibitory receptors. The contribution of the T cell receptor pathway and how this is integrated with other signaling events to influence HIV-1 infection and latency is a critical question that needs to be addressed.

Having a library of CARs with a range of binding affinities allowed us to determine if HIV-1 responds to signaling in an analog fashion correlating with signal input or is digitally

regulated by specific thresholds resulting in all-or-none responses [37]. Signaling through the CARs with affinities that were intermediate did not support active transcription despite a greater than 10-fold increase in binding affinity compared to our low affinity receptor. These results would suggest that TCR signaling provides more of an on/off switch in regulating HIV-1 transcription and that there exist signaling thresholds that must be overcome to assure efficient HIV-1 transcription and replication.

Signal transduction and gene expression are inherently noisy processes, and stochastic events are hypothesized to drive HIV-1 latency. That latency and HIV-1 replication are driven by episodic bursts of proviral transcription and Tat levels has been supported by mathematical modeling and experiments using engineered virus models [38–40]. Even if latency is driven by random fluctuations of provirus transcription, T cell associated signals are strong modulators of noise, and targeting these pathways could enhance treatments directed at HIV-1 reactivation [41]. Weak signaling, such as those induced by the low affinity chimeric antigen receptors, may be inadequate to alter the inherent noise within the system, whereas robust TCR signals through the high affinity CAR increase the probability of stochastic events. It is important to appreciate that although signaling and transcription are subject to stochastic variation, these are coordinated and combinatorial processes that lead to defined patterns of gene expression and phenotypic outcomes [42].

Regulated aspects of transcription include assembly of multi-subunit complexes such as RNAP II and associated cofactors, chromatin, and transcription factors at the LTR. Our data suggest that the association of NELF with RNAP II is regulated by TCR signaling. Multiple positive and negative signals are known to converge on NELF-driven transcriptional pausing. P-TEFb relieves NELF repression through phosphorylation [43] and is itself regulated by cellular stress and signals [44–46]. Furthermore, we have shown that NELF interacts with corepressors including NCoR1-GPS2-HDAC3 at the HIV-1 promoter [47] which may reinforce HIV-1 latency, especially during chronic infection, by facilitating post-translational modifications of histones and chromatin organization.

We propose that strength of signal at the time of infection acts as a bifurcating event leading to *either* robust transcription and the establishment of an inducible latent reservoir *or* minimal transcription and deep-seated latency. Our observations are consistent with the previous characterization of patient reservoirs that identified three subsets of latently infected cells: a small population of cells carrying inducible provirus, a larger population of cells with intact proviruses that are difficult to reactivate, and many defective proviruses [48]. Successful purging of the latent reservoir may require the use of a cocktail of latency reversing agents or the development of novel strategies to block reactivation [49–51].

Materials and methods

Cells

Jurkat CD4+ T cells (E6-1) and human embryonic kidney 293T cells were obtained from American Type Culture Collection (ATCC). Jurkat cells were cultured in RPMI 1640, 5% FBS (Corning, Inc.), 100 units/mL penicillin (Invitrogen), 100 µg/mL streptomycin (Invitrogen), and 2mM L-glutamine (Invitrogen). HEK293T cells were cultured in Dulbecco's Modified Eagle Medium, 10% FBS, 100 units/mL penicillin, 100 µg/mL streptomycin, and 2mM L-glutamine. Cells were grown at 37° C with 5% CO₂.

Primary CD4+ T cells were derived from de-identified healthy blood leukapheresis packs purchased from NY Biologic. Mononuclear cells were enriched from leukopaks by centrifuging through Histopaque gradient (Sigma-Aldrich). CD4+ T cells were isolated by negative selection using EasySep Human CD4+ T Cell Enrichment Kits from STEMCELL

Technologies. CD4⁺ cells were maintained in RPMI 1640, 10% FBS, 100 ^{units}/_{mL} penicillin, 100 ^{µg}/_{mL} streptomycin, and 2mM L-glutamine at 37° C with 5% CO₂. Prior to transduction with CARs, primary cells were supplemented with 10 ^{units}/_{mL} IL-2 and 10 ^{ng}/_{mL} IL-7. Following transduction, IL-2 was removed from most culture conditions. All cells and cell lines were split every 2–3 days.

Viruses and transductions

CARs were driven by a SFFV promoter in the lentiviral vector pHR [18,19]. pNL4-3.Luc.R-E- was obtained from NIH AIDS Reagent Program. BRU-ΔEnv-GFP has been described before [52]. Lentiviruses were made by transfection of vectors, VSV-G, Rev, Tat, and Gag-Pol constructs into HEK293T cells with 45µL polyethylenimine (1 ^{mg}/_{mL}) per 6x10⁶ cells. Supernatants were collected, filtered with 0.45µm syringe filter (Corning), concentrated by centrifuging through a 20% sucrose gradient, and titered with CEM cells [53]. We used a range of multiplicity of infections, but most viruses and lentiviruses within this paper were concentrated to approximately 1x10⁶ ^{IU}/_{mL}. HIV-1 viruses were made similarly but only required the viral plasmid and VSV-G.

For transductions with CAR vectors, a minimum of 1x10⁶ primary and Jurkat cells were stimulated for 5–6 h with 10 ^{µg}/_{mL} PHA, washed in PBS, and spinoculated with lentivirus and 5 ^{µg}/_{mL} polybrene (Millipore) at 1200g for 90 min. Cells were then supplemented with fresh RPMI and IL-7, cultured overnight, and washed in PBS 18 h later. Cells were rested for one week to return to a resting state as confirmed by low CD69 expression prior to HIV-1 infection.

CAR stimulation and infections

Non-tissue culture treated plates were coated overnight at 37° C with 1 ^{µg}/_{mL} Her2 (Recombinant Human ErbB2/Her2 Fc Chimera Protein from R&D Systems, 1129-ER). Her2 solution was removed from wells, plates were washed 3 times in PBS, and wells were blocked for 1 h with a 5% FBS-PBS solution.

Jurkat or primary CD4⁺ T cells were infected and simultaneously plated in Her2-treated wells. For experiments in which latently infected cells were generated, cells were spinoculated in the Her2-treated wells at 1200xg for 90 min and then supplemented with fresh RPMI and IL-7. Following overnight infection, cells were washed and either lysed or maintained in fresh media in the absence of Her2.

For reactivation of latent cells, mCherry (CAR) positive and GFP (HIV) negative cells were sorted at 6 or 7 days post HIV-1 infection. Cells were cultured with the following concentrations of LRAs: 5 ^{ng}/_{mL} PMA (Fisher Scientific) and either 10 or 100µM ionomycin (Sigma-Aldrich) for 2.5 h, Dynabeads human T-activator CD3/CD28 beads at a ratio to cells of 1:1 for 24 h, 50 µM SBHA (Sigma-Aldrich) for 24 h, and 25nM Bryostatins (Sigma-Aldrich) for 24 h. Cells reactivated with PMA were washed in PBS and re-plated in media. All reactivated cells were incubated with 10 ^{ng}/_{mL} IL-7. Cells were cultured overnight prior to fixation for flow analysis.

For some experiments, cells were treated with 10 µM PP2 or PP3 (Calbiochem—Millipore Sigma) at the time of infection.

Flow cytometry

Flow data were collected on an LSRII from BD Biosciences. Zombie UV Fixable Viability Kit (BioLegend) was used as live/dead stain for reactivation experiments. We had a range of 250 to 6000 events per data point and a minimum cut-off of 250 events in Fig 5B. The mean number

of all events was 1364 and the median number was 678. All cells were washed and fixed in a final concentration of 2% paraformaldehyde prior to analysis. Cell sorting was performed on a MoFlo Astrios from Beckman Coulter. All flow experiments performed at Boston University School of Medicine Flow Cytometry Core Facility.

Cell activation and phenotypes were determined by CD69 expression (Brilliant Violet 421 anti-human CD69 antibody; Clone FN50, BioLegend) and CCR7 and CD45RA expression (Pe/Cy7 anti-human CCR7 antibody; Clone G043H7, BioLegend and PerCP/Cy5.5 anti-human CD45RA antibody; Clone HI100, BioLegend). We had a minimum of 1000 events to be included as a data point in Fig 2.

Microarray analysis and heatmap formulation

Primary CD4⁺ T cells were transduced with CARs and allowed to return to a resting state for 1 week prior to cell sort. Cells were then stimulated overnight with plate-bound Her2 as described above. Untransduced CD4⁺ T cells were left unstimulated or were plated in a solution of 1 $\mu\text{g}/\text{mL}$ CD28 (Mouse Anti-Human CD28, #555725, BD Biosciences) on previously coated wells of 1 $\mu\text{g}/\text{mL}$ CD3 (Mouse Anti-Human CD3, #555329, BD Biosciences). We used a minimum input of 2.5×10^4 primary cells per experimental condition. Cells were then washed in PBS and lysed for RNA extraction using Qiagen miRNeasy Mini Kit (#217004). Microarrays and statistical support were provided by BU Microarray and Sequence Resource Core Facility. cDNA was made and samples were run on a Human Clariom S Array. Human Clariom S CEL files were normalized to unstimulated cells to produce gene-level expression values using the implementation of the Robust Multiarray Average (RMA) [54] in the *affy* package (version 1.36.1) [55] included in the Bioconductor software suite (version 2.11) [56] and an Entrez Gene-specific probe set mapping (21.0.0) from the Molecular and Behavioral Neuroscience Institute (Brainarray) at the University of Michigan [57, 58]. Array quality was assessed by computing Relative Log Expression (RLE) and Normalized Unscaled Error (NUSE) using the *affyPLM* package (version 1.34.0). Analyses of variance were performed using the *f.pvalue* function in the *sva* package (version 3.4.0). Differential expression was assessed by performing Student's *t* test on the coefficients of linear models created using the *lmFit* function in the *limma* package (version 3.14.4). In this way, a one-way ANOVA *p* value was obtained using a linear mixed effects modeling approach to account for differences between donors.

Correction for multiple hypothesis testing was accomplished using the Benjamini-Hochberg false discovery rate (FDR) [59]. All microarray analyses were performed using the R environment for statistical computing (version 2.15.1). All genes with FDR *q* values below 0.01 were plotted on a heatmap and arbitrarily separated into 5 clusters based on expression profiles.

Determination of gender was based upon log₂ expression of the Y-linked genes *DDX3Y*, *KDM5D*, *RPS4Y1*, *USP9Y*, and *UTY*.

Luciferase analysis

4×10^5 Jurkat cells were washed and lysed for luciferase analysis 24 h post infection, while 4×10^5 primary T cells were measured at 4 days post infection. Luciferin (Promega) was added and luciferase activity was measured via BioTek Synergy HT Microplate Reader.

Nested Alu-PCR

A minimum input of 8×10^5 cells per experimental condition was lysed in Tris-EDTA buffer prior to Alu-PCR. Nested PCR strategy was adapted from Agosto *et al.*, 2007 [20]. Briefly, integrated HIV-1 DNA was amplified using forward primers for the luciferase sequence and

reverse primers for human *Alu* (see [S1 File](#)). The first reaction was performed on a TProfessional Thermocycler from Biometra according to the following conditions: 4 m at 95° followed by 20 cycles of 15 s at 93°C, 15 s at 50°C, and 2.5 m at 70°C. A second round of amplification was then performed using a forward primer, a reverse primer, and a probe for real time PCR within the HIV-1 3' R / U5 region (see [S1 File](#)). The amount of amplified copies of HIV-1 was determined based on an NL4-3 plasmid copy standard. The second reaction was performed on an Applied Biosystems QuantStudio 3 Real-Time PCR system with heating for 4 m at 95° and real-time PCR conditions of denaturation for 15 s at 95°C, annealing for 30 s at 60°C, and extension for 1 m at 72°C.

RT-PCR

We lysed 1.5×10^5 cells per experimental condition in TRIzol Reagent (Invitrogen). RT-PCR for HIV-1 mRNA was performed using forward primers and reverse primers for unspliced HIV-1 *tat*, and all values were normalized against beta-actin as a housekeeping gene (see [S1 File](#)). The reaction was performed on an Applied Biosystems QuantStudio 3 Real-Time PCR system with heating for 15 m at 94°C and real-time PCR conditions of denaturation for 15 s at 94°C, annealing for 30 s at 60°C, and extension for 30 s at 72°C.

Chromatin immunoprecipitation

5×10^6 Jurkat cells were infected with NL4-3.Luc. ChIP was performed 24 h later according to Natarajan *et al.*, 2013 [47] with the addition of a nuclei isolation step using Farnham Lysis Buffer prior to sonication with a Bioruptor Pico. Specific details are listed in [S1 File](#). Antibodies used included anti-NELF-d (Antibody TH1L from Proteintech Group), anti-RNA Polymerase II antibody (Clone N20 from Santa Cruz Biotechnology), anti-histone H3 antibody (Product 06–599 from Millipore Sigma), and Normal Rabbit IgG (Product 12–370 from Millipore Sigma).

Primers used for the transcriptional start site include the forward primer at +30 and the reverse primer at +239. Primers used for transcriptional elongation include the forward and reverse primers within the *tat* gene (see [S1 File](#)).

Statistical analysis

Except for microarray analysis detailed above, all statistical analysis performed using unpaired Student's *t* test with significance thresholds of * $p < 0.01$, ** $p < 0.001$, and *** $p < 0.0001$. Because our experiments were performed on a sample population under the same conditions, we assumed that our data would be normally distributed. In agreement with this assumption, all experimental data points were less than 2 standard deviations from the mean. Where appropriate, normality was tested with a Shapiro-Wilk test.

Supporting information

S1 File. Supplemental materials and methods.
(PDF)

S1 Fig. Signaling through chimeric antigen receptors alters the expression of genes downstream from the T cell receptor. CD4+ T cells isolated from healthy human donors were transduced with low affinity or high affinity CARs and then allowed to return to a resting state as measured by CD69 expression. Cells were then stimulated through the receptor. As controls, untransduced cells were cultured with or without antibodies to CD3 and CD28. RNA was isolated 24 h later and converted to cDNA before being analyzed on a Human Clariom S

array. Gene expression levels for cells stimulated through both CARs and TCR-stimulated CD4+ T cells were compared to unstimulated cells. All genes with a one-way ANOVA FDR-corrected q value of < 0.01 were plotted and clustered arbitrarily according to expression profiles. Data is presented as a heatmap based on RNA log₂ expression and represents three independent donors. Donors 1 and 3 are female, while Donor 2 is male. Determination of donor gender is described in greater detail in Materials and Methods. See also [S1 Appendix](#) “List of genes whose expression is significantly altered upon TCR stimulation.”
(TIF)

S2 Fig. Src kinase inhibitor PP2 inhibits CAR-mediated HIV-1 transcription. CAR+ Jurkat T cells were stimulated with or without Her2 in the absence or presence of 10 μ M PP2 or PP3 at the time of HIV-1 infection with single-round VSV-G pseudotyped NL4-3.Luc. 24 h post infection, cells were lysed to measure luciferase. Data are presented as fold difference in RLU over unstimulated cells for each CAR+ population. S2 Fig was performed in triplicate and is representative of five independent experiments. Data are presented as mean \pm standard deviation. Statistical analysis performed using unpaired Student's t test and compared to Her2-stimulated conditions. * $p < 0.01$, ** $p < 0.001$, *** $p < 0.0001$.
(TIF)

S3 Fig. Robust T cell signaling at the time of HIV-1 infection generates a population of latently infected cells that are easily inducible. Latently infected cells were restimulated with PMA and ionomycin. HIV-1 expression was monitored by measuring Tat RNA by qRT-PCR. For each assay, the fold difference in HIV-1 transcripts over corresponding non-reactivated controls were normalized to the induction observed in the reactivated low-affinity condition. In this way, multiple assays could be directly compared in spite of differences in the level of induction measured due to donor-to-donor variability. The average fold increase in the level of induction observed in the high affinity population across all experiments is 5.23. Data in S3 Fig are presented as mean of 2–4 replicates and are derived from 3 different donors.
(TIF)

S1 Appendix. List of genes whose expression is significantly altered upon TCR stimulation. All genes shown in the microarray in [S1 Fig](#), each of which has a one-way ANOVA FDR-corrected q value of less than 0.01, is presented here. Each gene is listed along with its Human Entrez Gene ID, accepted description, and cluster number.
(XLSX)

Acknowledgments

We would like to thank the Boston University School of Medicine Flow Cytometry Core Facility for their contributions to the flow analysis and cell sorting experiments. The Boston University Microarray and Sequencing Resource Core Facility conducted both the microarray experiment and the analysis. Melissa Herring assisted with the kinase inhibitor assays. Kyle Pedro, Luis Agosto, PhD, and Gregory Viglianti, PhD (Boston University School of Medicine) provided advice regarding experimental design and the manuscript. The Providence/Boston CFAR (P30AI042853) provided technical support.

Author Contributions

Conceptualization: Matthew Gagne, Gillian M. Schiralli Lester, Suryaram Gummuluru, Wilson W. Wong, Andrew J. Henderson.

Formal analysis: Matthew Gagne, Andrew J. Henderson.

Funding acquisition: Matthew Gagne, Andrew J. Henderson.

Investigation: Matthew Gagne, Daniel Michaels, Gillian M. Schiralli Lester, Wilson W. Wong, Andrew J. Henderson.

Methodology: Matthew Gagne, Daniel Michaels, Gillian M. Schiralli Lester, Andrew J. Henderson.

Project administration: Andrew J. Henderson.

Resources: Andrew J. Henderson.

Supervision: Matthew Gagne, Wilson W. Wong, Andrew J. Henderson.

Validation: Matthew Gagne, Daniel Michaels, Gillian M. Schiralli Lester, Wilson W. Wong, Andrew J. Henderson.

Writing – original draft: Matthew Gagne, Andrew J. Henderson.

Writing – review & editing: Matthew Gagne, Suryaram Gummuluru, Wilson W. Wong, Andrew J. Henderson.

References

1. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. *Science*. 1997 Nov 14; 278(5341):1291–1295 PMID: [9360926](https://pubmed.ncbi.nlm.nih.gov/9360926/)
2. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. *Proc Natl Acad Sci USA*. 1997 Nov 25; 94(24):13193–13197. <https://doi.org/10.1073/pnas.94.24.13193> PMID: [9371822](https://pubmed.ncbi.nlm.nih.gov/9371822/)
3. Harrigan PR, Whaley M, Montaner JS. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. *AIDS*. 1999 May 28; 13(8):F59–F62. PMID: [10371167](https://pubmed.ncbi.nlm.nih.gov/10371167/)
4. Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, Costagliola D, et al. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. *AIDS*. 2008 Jun 19; 22(10):1125–1129. <https://doi.org/10.1097/QAD.0b013e3282fd6ddc> PMID: [18525257](https://pubmed.ncbi.nlm.nih.gov/18525257/)
5. Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. *PLoS ONE*. 2010 Feb 23; 5(2):e9390. <https://doi.org/10.1371/journal.pone.0009390> PMID: [20186346](https://pubmed.ncbi.nlm.nih.gov/20186346/)
6. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. *Nature*. 2012 Jul 25; 487(7408):482–485. <https://doi.org/10.1038/nature11286> PMID: [22837004](https://pubmed.ncbi.nlm.nih.gov/22837004/)
7. Quivy V, De Walque S, Van Lint C. Chromatin-associated regulation of HIV-1 transcription: implications for the development of therapeutic strategies. *Subcell Biochem*. 2007; 41:371–396. PMID: [17484137](https://pubmed.ncbi.nlm.nih.gov/17484137/)
8. Ruelas DS, Greene WC. An integrated overview of HIV-1 latency. *Cell*. 2013 Oct 24; 155(3):519–529. <https://doi.org/10.1016/j.cell.2013.09.044> PMID: [24243012](https://pubmed.ncbi.nlm.nih.gov/24243012/)
9. Agosto LM, Gagne M, Henderson AJ. Impact of chromatin on HIV replication. *Genes (Basel)*. 2015 Sep 30; 6(4):957–976. <https://doi.org/10.3390/genes6040957> PMID: [26437430](https://pubmed.ncbi.nlm.nih.gov/26437430/)
10. Cary DC, Fujinaga K, Peterlin BM. Molecular mechanisms of HIV latency. *J Clin Invest*. 2016 Feb; 126(2):448–454. <https://doi.org/10.1172/JCI80565> PMID: [26731470](https://pubmed.ncbi.nlm.nih.gov/26731470/)
11. Agosto LM, Henderson AJ. CD4+ T cell subsets and pathways to HIV latency. *AIDS Res Hum Retroviruses*. 2018 Jul 9. <https://doi.org/10.1089/aid.2018.0105> PMID: [29869531](https://pubmed.ncbi.nlm.nih.gov/29869531/)
12. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. *Proc Natl Acad Sci USA*. 1998 Jul 21; 95(15):8869–8873. <https://doi.org/10.1073/pnas.95.15.8869> PMID: [9671771](https://pubmed.ncbi.nlm.nih.gov/9671771/)
13. Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. *Nature*. 2014 Aug 7; 512(7512):74–77. <https://doi.org/10.1038/nature13594> PMID: [25042999](https://pubmed.ncbi.nlm.nih.gov/25042999/)
14. Huang Y, Wange RL. T cell receptor signaling: beyond complex complexes. *J Biol Chem*. 2004 Jul 9; 279(28):28827–28830. <https://doi.org/10.1074/jbc.R400012200> PMID: [15084594](https://pubmed.ncbi.nlm.nih.gov/15084594/)

15. Kim YK, Mbonye U, Hokello J, Karn J. T-cell receptor signaling enhances transcriptional elongation from latent HIV proviruses by activating P-TEFb through an ERK-dependent pathway. *J Mol Biol.* 2011 Jul 29; 410(5):896–916. <https://doi.org/10.1016/j.jmb.2011.03.054> PMID: 21763495
16. Allison KA, Sajti E, Collier JG, Gosselin D, Troutman TD, Stone EL, et al. Affinity and dose of TCR engagement yield proportional enhancer and gene activity in CD4+ T cells. *eLife.* 2016 Jul 4; 5:e10134. <https://doi.org/10.7554/eLife.10134> PMID: 27376549
17. Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. *Immunol Rev.* 2014 Jan; 257(1):83–90. <https://doi.org/10.1111/immr.12125> PMID: 24329791
18. Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. *J Mol Biol.* 1996 Nov 8; 263(4):551–567. <https://doi.org/10.1006/jmbi.1996.0598> PMID: 8918938
19. Chmielewski M, Hombach A, Heuser C, Adams GP, Abken H. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. *J Immunol.* 2004 Dec 15; 173(12):7647–7653. <https://doi.org/10.4049/jimmunol.173.12.7647> PMID: 15585893
20. Agosto LM, Yu JJ, Dai J, Kaletsky R, Monie D, O'Doherty U. HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. *Virology.* 2007 Nov 10; 368(1):60–72. <https://doi.org/10.1016/j.virol.2007.06.001> PMID: 17631931
21. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, et al. HIV preferentially infects HIV-specific CD4+ T cells. *Nature.* 2002 May 2; 417(6884):95–98. <https://doi.org/10.1038/417095a> PMID: 11986671
22. Demoustier A, Gubler B, Lambotte O, de Goër MG, Wallon C, Goujard C, et al. In patients on prolonged HAART, a significant pool of HIV infected CD4 T cells are HIV- specific. *AIDS.* 2002 Sep 6; 16(13):1749–1754. PMID: 12218385
23. Casazza JP, Brenchley JM, Hill BJ, Ayana R, Ambrozak D, Roederer M, et al. Autocrine production of β -chemokines protects CMV-Specific CD4+ T cells from HIV infection. *PLoS Pathog.* 2009 Oct; 5(10):e1000646. <https://doi.org/10.1371/journal.ppat.1000646> PMID: 19876388
24. Geldmacher C, Ngwenyama N, Schuetz A, Petrovas C, Reither K, Heeregrave EJ, et al. Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. *J Exp Med.* 2010 Dec 20; 207(13):2869–2881. <https://doi.org/10.1084/jem.20100090> PMID: 21115690
25. Hu H, Liu F, Kim J, Ratto-Kim S. HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response. *Expert Rev Vaccines.* 2016 Jun; 15(6):709–717. <https://doi.org/10.1586/14760584.2016.1147354> PMID: 26814372
26. Laurence J, Hodtsev AS, Posnett DN. Superantigen implicated in dependence of HIV-1 replication in T cells on TCR V β expression. *Nature.* 1992 Jul 16; 358(6383):255–259. <https://doi.org/10.1038/358255a0> PMID: 1630494
27. Saleh S, Solomon A, Wightman F, Xhilaga M, Cameron PU, Lewin SR. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. *Blood.* 2007 Dec 15; 110(13):4161–4164. <https://doi.org/10.1182/blood-2007-06-097907> PMID: 17881634
28. Bosque A, Planelles V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. *Blood.* 2009 Jan 1; 113(1):58–65. <https://doi.org/10.1182/blood-2008-07-168393> PMID: 18849485
29. Pace MJ, Agosto L, Graf EH, O'Doherty U. HIV reservoirs and latency models. *Virology.* 2011 Mar 15; 411(2):344–354. <https://doi.org/10.1016/j.virol.2010.12.041> PMID: 21284992
30. Agosto LM, Herring MB, Mothes W, Henderson AJ. HIV-1-infected CD4+ T cells facilitate latent infection of resting CD4+ T cells through cell-cell contact. *Cell Rep.* 2018 Aug 21; 24(8):2088–2100. <https://doi.org/10.1016/j.celrep.2018.07.079> PMID: 30134170
31. Kumar NA, van der Sluis RM, Mota T, Pascoe R, Evans VA, Lewin SR, et al. Myeloid dendritic cells induce HIV latency in proliferating CD4+T cells. *J Immunol.* 2018 Sep 1; 201(5):1468–1477. <https://doi.org/10.4049/jimmunol.1701233> PMID: 30030324
32. Biberfeld P, Chayt KJ, Marselle LM, Biberfeld G, Gallo RC, Harper ME. HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy. *Am J Pathol.* 1986 Dec; 125(3):436–442. PMID: 3642987
33. Shen A, Zink MC, Mankowski JL, Chadwick K, Margolick JB, Carruth LM, et al. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. *J Virol.* 2003 Apr; 77(8):4938–4949. <https://doi.org/10.1128/JVI.77.8.4938-4949.2003> PMID: 12663799

34. Aid M, Dupuy FP, Moysi E, Moir S, Haddad EK, Estes JD, et al. Follicular CD4 T helper cells as a major HIV reservoir compartment: a molecular perspective. *Front Immunol*. 2018 Jun 18; 9:895. <https://doi.org/10.3389/fimmu.2018.00895> PMID: 29967602
35. Zehn D, Lee SY, Bevan MJ. Complete but curtailed T-cell response to very low-affinity antigen. *Nature*. 2009 Mar 12; 458(7235):211–214. <https://doi.org/10.1038/nature07657> PMID: 19182777
36. Martinez RJ, Andargachew R, Martinez HA, Evavold BD. Low-affinity CD4+ T cells are major responders in the primary immune response. *Nat Commun*. 2016 Dec 15; 7:13848. <https://doi.org/10.1038/ncomms13848> PMID: 27976744
37. Zikherman J, Au-Yeung B. The role of T cell receptor signaling thresholds in guiding T cell fate decisions. *Curr Opin Immunol*. 2015 Apr; 33:43–48. <https://doi.org/10.1016/j.coi.2015.01.012> PMID: 25660212
38. Burnett JC, Miller-Jensen K, Shah PS, Arkin AP, Schaffer DV. Control of stochastic gene expression by host factors at the HIV promoter. *PLoS Pathog*. 2009 Jan; 5(1):e1000260. <https://doi.org/10.1371/journal.ppat.1000260> PMID: 19132086
39. Donahue DA, Kuhl BD, Sloan RD, Wainberg MA. The viral protein Tat can inhibit the establishment of HIV-1 latency. *J Virol*. 2012 Mar; 86(6):3253–3263. <https://doi.org/10.1128/JVI.06648-11> PMID: 22238306
40. Razoooky BS, Pai A, Aull K, Rouzine IM, Weinberger LS. A hardwired HIV latency program. *Cell*. 2015 Feb 26; 160(5):990–1001. <https://doi.org/10.1016/j.cell.2015.02.009> PMID: 25723172
41. Dar RD, Hosmane NN, Arkin MR, Siliciano RF, Weinberger LS. Screening for noise in gene expression identifies drug synergies. *Science*. 2014 Jun 20; 344(6190):1392–1396. <https://doi.org/10.1126/science.1250220> PMID: 24903562
42. Banos A, Agelopoulos M, Thanos D. Stochastic responses are not left to pure “chance.” *Cell*. 2013 Oct 24; 155(3):499–502. <https://doi.org/10.1016/j.cell.2013.10.002> PMID: 24243008
43. Fujinaga K, Irwin D, Huang Y, Taube R, Kurosu T, Peterlin BM. Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element. *Mol Cell Biol*. 2004 Jan; 24(2):787–795. <https://doi.org/10.1128/MCB.24.2.787-795.2004> PMID: 14701750
44. Garriga J, Peng J, Parreño M, Price DH, Henderson EE, Graña X. Upregulation of cyclin T1/CDK9 complexes during T cell activation. *Oncogene*. 1998 Dec 17; 17(24):3093–3102. <https://doi.org/10.1038/sj.onc.1202548> PMID: 9872325
45. Zhou Q, Yik JHN. The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. *Microbiol Mol Biol Rev*. 2006 Sep; 70(3):646–659. <https://doi.org/10.1128/MMBR.00011-06> PMID: 16959964
46. Fujinaga K, Luo Z, Schaufele F, Peterlin BM. Visualization of positive transcription elongation factor b (P-TEFb) activation in living cells. *J Biol Chem*. 2015 Jan 16; 290(3):1829–1836. <https://doi.org/10.1074/jbc.M114.605816> PMID: 25492871
47. Natarajan M, Schiralli Lester GM, Lee C, Missra A, Wasserman GA, Steffen M, et al. Negative elongation factor (NELF) coordinates RNA polymerase II pausing, premature termination, and chromatin remodeling to regulate HIV transcription. *J Biol Chem*. 2013 Sep 6; 288(36):25995–26003. <https://doi.org/10.1074/jbc.M113.496489> PMID: 23884411
48. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DIS, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. *Cell*. 2013 Oct 24; 155(3):540–551. <https://doi.org/10.1016/j.cell.2013.09.020> PMID: 24243014
49. Xing S, Siliciano RF. Targeting HIV latency: pharmacologic strategies toward eradication. *Drug Discov Today*. 2013 Jun; 18(11–12):541–551. <https://doi.org/10.1016/j.drudis.2012.12.008> PMID: 23270785
50. Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, et al. An in-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified bryostatin-1+JQ1 and ingenol-B+JQ1 to potently reactivate viral gene expression. *PLOS Pathog*. 2015 Jul 30; 11(7):e1005063. <https://doi.org/10.1371/journal.ppat.1005063> PMID: 26225566
51. Darcis G, Van Driessche B, Van Lint C. HIV latency: should we shock or lock? *Trends Immunol*. 2017 Mar; 38(3):217–228. <https://doi.org/10.1016/j.it.2016.12.003> PMID: 28073694
52. Akiyama H, Miller CM, Ettinger CR, Belkina AC, Snyder-Cappione JE, Gummuluru S. HIV-1 intron-containing RNA expression induces innate immune activation and T cell dysfunction. *Nat. Commun*. 2018 Aug 27; 9(1):3450. <https://doi.org/10.1038/s41467-018-05899-7> PMID: 30150664
53. Janas AM, Wu L. HIV-1 interactions with cells: from viral binding to cell-cell transmission. In: *Current Protocols in Cell Biology*. John Wiley & Sons, Inc.; 2009 Jun. 26. 5.

54. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics*. 2003 Apr; 4(2):249–264. <https://doi.org/10.1093/biostatistics/4.2.249> PMID: 12925520
55. Gautier L, Cope L, Bolstad BM, Irizarry RA. *affy*—analysis of Affymetrix GeneChip data at the probe level. *Bioinformatics*. 2004 Feb 12; 20(3):307–315. <https://doi.org/10.1093/bioinformatics/btg405> PMID: 14960456
56. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol*. 2004; 5(10):R80. <https://doi.org/10.1186/gb-2004-5-10-r80> PMID: 15461798
57. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. *Nucleic Acids Res*. 2005 Nov 10; 33(20):e175. <https://doi.org/10.1093/nar/gni179> PMID: 16284200
58. Brainarray [Internet]. Ann Arbor (MI): Molecular and Behavioral Neuroscience Institute, University of Michigan. [cited 2019 Feb 16]. Available from: <http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF>
59. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *J R Stat Soc Series B Stat Methodol*. 1995; 57(1):289–300.